NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Investors of record on Friday, June 15th will be given a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its Board of Directors has initiated a stock repurchase program on Saturday, December 2nd 2017, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's board of directors believes its stock is undervalued.

Merck & Co., Inc. (NYSE:MRK) released its earnings results on Tuesday, May, 1st. The company reported $1.05 EPS for the quarter, topping the Zacks' consensus estimate of $1.00 by $0.05. The business earned $10.04 billion during the quarter, compared to analyst estimates of $10.09 billion. Merck & Co., Inc. had a net margin of 4.31% and a return on equity of 30.93%. The company's revenue was up 6.4% on a year-over-year basis. During the same period last year, the company earned $0.88 earnings per share. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 analysts have issued 12-month target prices for Merck & Co., Inc.'s stock. Their forecasts range from $58.83 to $72.00. On average, they expect Merck & Co., Inc.'s stock price to reach $66.0519 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Ratings for Merck & Co., Inc..

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Merck & Co., Inc. saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 17,153,866 shares, a drop of 21.6% from the June 15th total of 21,867,505 shares. Based on an average daily trading volume, of 11,109,077 shares, the short-interest ratio is presently 1.5 days. Currently, 0.6% of the company's shares are short sold. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about MRK stock has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merck & Co., Inc. earned a media sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the company an impact score of 46.07 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Merck & Co., Inc.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), Bank of Montreal Can (0.14%), NN Investment Partners Holdings N.V. (0.08%), Retirement Systems of Alabama (0.08%) and Manning & Napier Group LLC (0.07%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Hartford Investment Management Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Stralem & Co. Inc., Manning & Napier Group LLC, Nippon Life Global Investors Americas Inc., Radnor Capital Management LLC and Highland Capital Management LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, Nisa Investment Advisors LLC, LGT Capital Partners LTD., Retirement Systems of Alabama, Calamos Advisors LLC, DnB Asset Management AS and Welch & Forbes LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $62.41.

Merck & Co., Inc. has a market capitalization of $169.70 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]